Finance entity
Sentiment skews less negative than the wider beat, at 0% negative against 26% across all 4693 Finance stories in the same window. The clearest coverage concentration is markets: 9 of 15 stories, with the rest divided among 1 other category.
Last mentioned: 2d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Sentiment skews less negative than the wider beat, at 0% negative against 26% across all 4693 Finance stories in the same window. The clearest coverage concentration is markets: 9 of 15 stories, with the rest divided among 1 other category. Truist Financial is most often covered alongside Weiss Ratings, which appears in 7 of these 15 stories. Each story carries 2.1 original sources on average, compared with 2.7 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6.2 for that window. That works out to roughly 0.5 stories per week across a 203-day span. The busiest single day carried 2. We currently track 15 Finance stories that mention Truist Financial, published between February 19, 2026 and September 9, 2026.
Computed from the 15 stories linked to this entity, with beat comparisons drawn from all 4693 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Truist Financial. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen issues opposing ratings
Downgraded T1 Energy from Sell to Strong Sell and upgraded SM Energy from Buy to Strong Buy.
T1 Energy earnings and BTIG target move
T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.
Truist raises SM Energy target
Increased price target from $37.00 to $43.00 and maintained a Buy rating.
Wall Street Zen downgrades to Hold
Wall Street Zen cut both Klaviyo and Oceaneering International from Buy to Hold in Saturday research notes.
Citigroup lifts KVYO target
Citigroup raised its Klaviyo price target from $34.00 to $36.00 with a Buy rating.
KVYO analyst revisions
Stephens, BTIG, Stifel, and Truist adjusted price targets on Klaviyo following earnings.
Klaviyo Q2 earnings
Klaviyo reported EPS of $0.19, meeting consensus, and revenue of $370.58 million.
SM Energy quarterly results
SM Energy reported $2.19 earnings per share for the quarter.
OII insider sale
SVP Christopher J. Dyer sold 1,200 OII shares at an average price of $47.65 for $57,180.
Weiss upgrades OII
Weiss Ratings raised OII from Buy (B-) to Buy (B).
Barclays lifts OII target
Barclays increased its OII price objective from $39.00 to $47.00 with an Equal Weight rating.
Two updates on SM Energy
Susquehanna lifted its SM target from $31 to $32 (Neutral); Raymond James lowered its target from $55 to $48 (Outperform).
UBS initiates SM Energy
Started coverage with a Buy rating and a $36.00 target price.
Weiss Ratings reaffirms T1 Energy sell
Reaffirmed a Sell (D-) rating on T1 Energy.
Citigroup raises OII target
Citigroup raised its Oceaneering target from $35.00 to $40.00 with a Neutral rating.
Bernstein assumes T1 Energy coverage
Set a Market Perform rating and a $9.00 price objective.
Northland Securities initiates T1 Energy
Started coverage with an Outperform rating and a $16.00 price objective.
Zacks Research upgrades T1 Energy
Moved T1 Energy from Strong Sell to Hold.
Siebert Williams Shank upgrades SM Energy
Raised SM Energy from Hold to Buy and lifted target price from $30.00 to $41.00.
TD Cowen lifts OII target
TD Cowen raised its Oceaneering International price target from $34.00 to $36.00 with a Hold rating.
A Sunday morning research note lifted Wall Street Zen's view on two biotechs—argenx to buy and Tenaya from strong sell to sell—but the market implications diverge sharply. Finance readers get a comparison of a profitable $63 billion rare-disease leader trading at a 38.67 P/E against a $148.75 million speculative gene therapy name at -1.25 P/E.
Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Source: themarketsdaily.com · dailypolitical.com
A Q2 2026 13F filing reveals Wyoming's $1.08 million new stake in Antero Resources amid a wave of institutional accumulation. Large asset managers such as Assenagon and AQR boosted AR positions by triple-digit percentages, while institutional ownership sits at 83.04%. The cluster provides a proxy for natural gas equity positioning and the nuance behind 13F season flows.
Source: tickerreport.com · dailypolitical.com
Globant reported EPS of $1.40, missing consensus by $0.10, while revenue of $614.42 million slightly beat estimates but was flat year over year. Shares fell 8.9% to $37.35 as analysts lowered price targets. The company reiterated FY2026 EPS guidance of $5.75-$6.15 and Q3 guidance of $1.43.
Source: themarketsdaily.com · dailypolitical.com
Wall Street Zen downgraded both Oceaneering International and Klaviyo from Buy to Hold, spotlighting two $5 billion market-cap companies with vastly different P/E ratios—14.59 for OII and 895.95 for KVYO. The ratings actions come as consensus targets diverge from current prices.
Source: dailypolitical.com · themarketsdaily.com
SoFi Technologies shares jumped 3.7% on August 4, 2026, even as multiple analysts slashed price targets, creating a tension between market momentum and cautious research. With a PE of 38.96, beta of 2.17, and consensus Hold rating, the fintech’s next move hinges on whether profitability can catch up with valuation.
Source: tickerreport.com · dailypolitical.com
Construction Partners (ROAD) posted a $0.07 EPS surprise and 28.2% revenue growth, yet analyst downgrades and price target cuts cloud the outlook. The stock's low PEG ratio of 0.85 contrasts with a high debt load and thin margins, creating a complex picture for value and growth investors.
Source: themarketsdaily.com · dailypolitical.com
Grand Canyon Education shares fell to $150.13 after Q3 EPS guidance of $1.74-$1.78 missed the $1.83 consensus. The company lifted its FY 2026 EPS outlook above expectations, creating a mixed investment signal. Analysts remain moderately bullish with a $171.67 consensus target.
Collegium Pharmaceutical delivered an 11.6% EPS beat and modest revenue beat, lifting shares to $29.47. High ROE and institutional accumulation offset by high leverage and mixed analyst ratings create a nuanced investment case.
Astronics Corporation's share price vaulted 7.8% on June 11, 2026, to $88.76, with analysts split between a $100 high target and a sell rating. The company's 6-for-5 stock split, effective June 15, adds to the excitement, but low volume and high P/E warrant caution for value investors.
Source: tickerreport.com · dailypolitical.com
Bloom Energy shares popped 6.5% on 46% higher volume to $219.22, reigniting the debate about its $62.36B valuation amid a bull-bear analyst divide. With price targets spanning $188 to $310 and a P/E near 292, the AI-driven stock offers high risk and high potential reward.
Sun Communities’ FY 2026 EPS guidance of $6.94–$7.10 beat the $6.93 consensus, but shares fell 0.4% on heavy volume as revenue guidance was absent. Analyst targets average $140.05, suggesting 15% upside from $121.30 despite recent price target cuts.
Source: MarketBeat · themarketsdaily.com
Monarch Casino & Resort posted a second-quarter earnings beat of $0.11 per share on revenue strength, driving the stock up 1.1% to $124.38. Valuation metrics remain solid with a P/E of 21.08 and a 1% dividend yield, but a recent CEO stock sale and mixed analyst ratings signal a cautious bias. Truist’s $144 price target offers the most bullish outlook, while Stifel sits at $102.
Source: MarketBeat · tickerreport.com
Robinhood shares fell 8.2% despite a wave of analyst upgrades and a $95.5B market cap. The stock’s high beta of 2.33 suggests volatility, but bullish targets as high as $137 may offer a buying opportunity for risk-tolerant investors.
Waystar (NASDAQ: WAY) is navigating a divided Wall Street as Needham & Company lowered its price target to $33.00, citing potential growth headwinds. This move contrasts with Truist Financial's $38.00 valuation, highlighting a widening gap in expectations for the healthcare payment platform's market penetration.
Truist Financial is linked from 15 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
